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y 8, 2013.he present study aimed to develop a comprehensive clinical risk score for vasospastic angina (VSA) patients.Background Previous studies demonstrated various prognostic factors of future adverse events in VSA patients. However, to
apply these prognostic factors in clinical practice, the assessment of their accumulation in individual patients is
important.Methods The patient database of the multicenter registry study by the Japanese Coronary Spasm Association (JCSA)
(n ¼ 1,429; median 66 years; median follow-up 32 months) was utilized for score derivation.Results Multivariable Cox proportional hazard model selected 7 predictors of major adverse cardiac events (MACE). The
integer score was assigned to each predictors proportional to their respective adjusted hazard ratio; history of out-
of-hospital cardiac arrest (4 points), smoking, angina at rest alone, organic coronary stenosis, multivessel spasm
(2 points each), ST-segment elevation during angina, and beta-blocker use (1 point each). According to the total
score in individual patients, 3 risk strata were deﬁned; low (score 0 to 2, n ¼ 598), intermediate (score 3 to 5, n ¼
639) and high (score 6 or more, n ¼ 192). The incidences of MACE in the low-, intermediate-, and high-risk patients
were 2.5%, 7.0%, and 13.0%, respectively (p < 0.001). The Cox model for MACE between the 3 risk strata also
showed prognostic utility of the scoring system in various clinical subgroups. The average prediction rate of the
scoring system in the internal training and validation sets were 86.6% and 86.5%, respectively.Conclusions We developed a novel scoring system, the JCSA risk score, which may provide the comprehensive risk assessment
and prognostic stratiﬁcation for VSA patients. (J Am Coll Cardiol 2013;62:1144–53) ª 2013 by the American
College of Cardiology FoundationVasospastic angina (VSA) is one of the important functional
cardiac disorders characterized by transient myocardial
ischemia due to epicardial coronary artery spasm (1–3). The
terms for VSA are basically synonymous with the terms
Prinzmetal’s angina and variant angina, and is known to
be associated with a wide variety of cardiac conditions,te School of Medicine, Sendai, Japan; yNational
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threatening arrhythmic events (4,5).
A number of studies have elucidated patient character-
istics, outcomes, and prognostic factors of VSA (6–12),
which led to a better understanding and management for
this disorder. We have also recently reported the prognostic
importance of the history of out-of-hospital cardiac arrest
(OHCA) (13) and speciﬁc angiographic ﬁndings during
diagnostic testing (14) in VSA patients from the multi-
center registry study with more than 1,400 patients.
However, because the patient characteristics and the
number of prognostic factors present in individual patients
may vary and the potential interaction between each
prognostic factor may exist, it is difﬁcult to accurately
evaluate risk stratiﬁcation of VSA patients in the current
clinical practice. Thus, the comprehensive assessment tool
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1145that provides a valid risk prediction in individual patients
needs to be developed. As one of the useful means to assess
the comprehensive risk, simple scoring models, in which
the prognostic factors identiﬁed by multivariable analysis
are combined, have been developed for several disorders
(15), although there is currently no tool available for VSA
patients.
In the present study, we thus aimed to develop
a comprehensive clinical risk scoring system that provides
the prediction of future adverse cardiac events and the
prognostic stratiﬁcation for VSA patients in the nationwide
multicenter registry study conducted by the Japanese
Coronary Spasm Association (JCSA).OHCA = out-of-hospital
cardiac arrest
SD = standard deviation
VSA = vasospastic anginaMethods
The JCSA was founded in 2006 and currently consists of
81 institutes in Japan. The present study was conducted as
an investigator initiated observational clinical research. The
study was approved by the institutional review boards or
ethics committees of all participating institutes.
Study patients. The VSA patients diagnosed between
April 1, 2003, and December 31, 2008 were enrolled. The
registration was made between September 1, 2007, and
December 31, 2008. The data collection was conducted in
a retrospective fashion for patients seen before September
2007 and in a prospective manner for those seen after that
date. The diagnosis of VSA was made based on the spasm
provocation tests and/or spontaneous angina attack deﬁned
by the Guidelines for Diagnosis and Treatment of Patients
with Vasospastic Angina of the Japanese Circulation Society
(16). The positive diagnosis of the provocation tests was
deﬁned as a total or subtotal (>90%) coronary artery nar-
rowing induced by pharmacological (e.g., acetylcholine and
ergonovine) or nonpharmacological (e.g., hyperventilation)
challenge during coronary angiography, accompanied by
chest pain and/or ischemic electrocardiography (ECG)
changes. The deﬁnition of spontaneous attack was angina at
rest and/or effort, accompanied by a transient ST-segment
elevation or depression of more than 0.1 mV, or a new
appearance of negative U-wave on ECG (16). The criterion
of spontaneous attack was applied when the patients did not
have signiﬁcant organic coronary stenosis that can explain
their angina attacks.
Data collection. The demographic and clinical data were
submitted to a central database system, including age, sex,
coronary risk factors, types of angina episodes, ST-segment
changes and arrhythmias during spontaneous angina attack,
angiographic ﬁndings of the spasm provocation tests,
medications, and device therapy such as implantable car-
dioverter deﬁbrillator (ICD). The clinical outcomes during
the follow-up period were also collected. Follow-up data
were obtained from each participating or cooperating
hospital records and patients’ regular visits to physicians in
the outpatient clinic. The outcomes of the retrospectivepopulation were evaluated retro-
spectively. The prospective cohort
was followed up until December
31, 2008.
Hypertension, dyslipidemia, and
diabetes mellitus were diagnosed
based on the guidelines of the
Japanese Society of Hypertension,
Japan Atherosclerosis Society, and
Japan Diabetes Society, respectively
(17–19). The OHCA was deﬁned
as the cessation of cardiac mech-
anical activity, as conﬁrmed by
the absence of signs of circu-
lation that occurred outside of
the hospital setting (20). Organic
coronary stenosis was assessed as
either nonsigniﬁcant (25% to
50% luminal narrowing) or signiﬁcant (more than 50%
luminal narrowing) by coronary angiography.
Endpoints. The primary endpoint was deﬁned as major
adverse cardiac events (MACE), including cardiac death,
nonfatal myocardial infarction, hospitalization due to
unstable angina pectoris, heart failure, and the appropriate
ICD shocks during the follow-up period that began at
the date of the diagnosis of VSA. In particular, cardiac
death, nonfatal myocardial infarction and ICD shocks were
categorized as hard MACE. The secondary endpoint was
all-cause mortality. The deﬁnition of these events was
previously described (13).
Statistical analysis. Continuous variables are presented as
medians and interquartile ranges (IQR) or means and stan-
dard deviations (SD) and categorical variables as numerals
and percentages. Group comparisons were performed with
the Kruskal-Wallis test for continuous variables, the chi-
square test for categorical variables, and the log-rank test for
survival curves. Survival free from MACE and death were
analyzed by the Kaplan-Meier method. A value of p < 0.05
was considered to be statistically signiﬁcant.
The clinical variables included in our JCSA risk score
and respective scoring points were determined based on
their prognostic contribution for VSA patients. Univariable
and multivariable Cox proportional hazard model were
applied to select the demographic and angiographic char-
acteristics and treatments that correlated with MACE. The
variables showing statistical signiﬁcance or a trend (p <
0.1) in univariable Cox model were subjected to multivar-
iable analysis with a forced-entry method. The Akaike
Information Criterion (AIC) was used to select appropriate
explanatory variables (21). Missing data were handled using
a multiple imputation procedure with 20 resampling
replications. The proportional hazards assumption for the
Cox model was examined with the log minus log plot.
Signiﬁcant variables selected from multivariable Cox model
were assigned integer score proportional to their adjusted
hazard ratio (HR) for MACE. The variables with
Table 1
Demographic and Angiographic Characteristics
and Treatments of VSA Patients (N = 1,429)
Demographic characteristics
Age, yrs 66 (58, 73)
Male 1,090 (76)
Coronary risk factor
Hypertension 666 (47)
Dyslipidemia 647 (45)
Diabetes mellitus 233 (16)
Smoking 848 (59)
Previous myocardial infarction 91 (6)
Clinical situation of angina attack*
Rest 634 (50)
Effort 113 (9)
Rest and effort 513 (41)
ST-segment change during angina attacky
ST-segment elevation 272 (21)
ST-segment depression 121 (9)
Arrhythmic event during angina attack
PVC 14 (1)
VT/VF 43 (3)
AV block 21 (1)
Bradycardia/sinus pause 28 (2)
OHCA 35 (2)
Angiographic characteristics
Organic coronary stenosis
Without stenosis 878 (61)
Nonsigniﬁcant stenosis 350 (25)
Signiﬁcant stenosis 201 (14)
Spasm-positive artery induced
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1146a statistical trend were uniformly deﬁned as 1 point. Then
the score was calculated in individual patients by the sum of
weighted variables present. The differences in the incidence
of MACE and death for increasing the JCSA risk score
were assessed by the chi-square test for trend. Relative
hazard for MACE between 3 risk strata deﬁned by the
range of risk score was estimated by the univariable Cox
model. The interaction between the risk strata and pre-
deﬁned clinical subgroups in their effects on MACE was
assessed by the Cox model with interaction terms.
The validity of the scoring system was assessed by the
simulation study, which was formed with the iteration of
random partition of the data into training and validation sets
(22). First, we divided the whole population data of 1,429
patients into 1,286 training (90%) and 143 validation (10%)
sets, the latter of which was completely set aside during
training. To train the model, the Cox proportional hazard
model was applied to the training set with the clinical
variables that were included in the JCSA risk score. Adjusted
HR and respective scoring points for each variable were
determined by exactly the same method for the aforemen-
tioned full model. The JCSA risk score obtained from the
training data was applied to the samples in the validation set
and the corresponding risk strata were predicted for each
sample. This process was iterated 1,000 times and the
average prediction rate and its SD predicting correct risk
strata were calculated. We also calculated the average inci-
dence of MACE in each predicted risk stratum.by provocation testz
LAD 666 (56)
LCx 317 (27)
RCA 693 (59)
Multivessel 374 (32)
Medical treatments
Calcium-channel blocker 1,331 (93)
Long-acting nitrate 695 (49)
Antiplatelet 669 (47)
Statin 472 (33)
ACEI/ARB 340 (24)
Beta-blocker 61 (4)
Values are median (IQR) or n (%). *Data of clinical situation of angina attacks were available for
1,260 patients. yData of ST-segment changes were available for 1,317 patients. zThe spasm
provocation test was performed on 1,244 patients, and the data of spasm-positive artery were
available for 1,184 patients.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; AV ¼
atrioventricular; IQR ¼ interquartile range; LAD ¼ left anterior descending artery; LCx ¼ left
circumﬂex coronary artery; OHCA ¼ out-of-hospital cardiac arrest; PVC ¼ premature ventricular
contraction; RCA ¼ right coronary artery; VF ¼ ventricular ﬁbrillation; VSA ¼ vasospastic angina;
VT ¼ ventricular tachycardia.Results
Patient characteristics and treatments. Among the 1,528
patients registered from 47 participating hospitals, 99 were
excluded because they did not meet the inclusion criteria.
Finally, 1,429 VSA patients, including retrospective
(n ¼ 1,276) and prospective populations (n ¼ 153), were
analyzed in the present study. The demographic and
angiographic characteristics and treatments of the study
patients are summarized in Table 1 and Online Table 1.
The median age was 66 years. Angina attack occurred at
rest alone was noted in 634 patients. The ST-segment
changes were documented in 393 patients during sponta-
neous angina attacks. The arrhythmic events were observed
in 107 patients, of which 52 suffered from life-threatening
events including ventricular tachycardia, ventricular ﬁbril-
lation, and OHCA. All the patients underwent coronary
angiography, and the spasm provocation tests were per-
formed in 1,244 patients. Signiﬁcant organic coronary
stenosis was found in 201 patients. Of those, 180 patients
were diagnosed by performing the provocation test, and the
remaining 21 patients were diagnosed based on sponta-
neous attacks. For the treatment of VSA, calcium channel
blockers were used in 1,331 patients, whereas the use of
beta-blockers was limited to 61. In 35 patients with
a history of OHCA, 14 underwent ICD implantation for
the secondary prevention of sudden cardiac death.Long-term outcomes and correlated factors of MACE.
During the median follow-up period of 32 months (IQR: 17
to 46 months), 85 patients (5.9%) reached the primary
endpoint (Table 2), of those 14 patients (1.0%) suffered from
hard MACE. All-cause death as the secondary endpoint
occurred in 19 patients (1.3%). Kaplan-Meier analysis
demonstrated that the 5-year survival rate free from MACE
and all-cause death were 91% and 98%, respectively. The
Table 2
Primary and Secondary Outcomes During the
Follow-Up Period (N = 1,429)
MACE 85 (6)
Cardiac death 6 (0.4)
Nonfatal myocardial infarction 9 (1)
Unstable angina 68 (5)
Heart failure 4 (0.3)
Appropriate ICD shock 2 (0.1)
All-cause death 19 (1)
Values are n (%).
ICD ¼ implantable cardioverter-deﬁbrillator; MACE ¼ major adverse cardiac event; other
abbreviations as in Table 1.
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coronary stenosis are summarized in Online Table 2.
The patient characteristics and the treatments associ-
ated with the primary endpoint at univariable and
multivariable analysis are shown in Table 3. Multivariable
Cox model demonstrated 5 signiﬁcant predictors of
MACE, including smoking, angina at rest alone, history
of OHCA, signiﬁcant organic coronary stenosis, and
multivessel spasm. The ST-segment elevation during
angina attack and the use of beta-blockers also tended to
have a prognostic impact, although statistical signiﬁcance
was not derived. The covariates included in the ﬁnal
multivariable model were determined by reference to
AIC. At ﬁrst, a model was considered with 9 variables
including diabetes mellitus and previous myocardial
infarction. However, exclusion of these 2 variables resul-
ted in a reduction of AIC from 1,155.08 to 1,153.15Table 3 Correlated Factors for MACE in VSA Patients and Assigned
Univariable Analysis
HR 95% CI p Value
Age 0.99 0.97–1.01 0.38
Male 1.07 0.64–1.79 0.79
Hypertension 0.90 0.58–1.38 0.62
Dyslipidemia 1.17 0.76–1.79 0.48
Diabetes mellitus 1.57 0.94–2.61 0.09
Smoking 1.96 1.21–3.19 0.006
Previous myocardial infarction 2.19 1.10–4.38 0.026
Angina at rest alone 1.49 0.95–2.35 0.09
ST-segment elevation during
angina attack
1.50 0.93–2.42 0.09
History of OHCA 3.98 1.73–9.13 0.001
Signiﬁcant organic stenosis 2.28 1.39–3.73 0.001
LAD spasm 1.28 0.81–2.02 0.29
LCx spasm 1.16 0.75–1.80 0.50
RCA spasm 1.05 0.68–1.61 0.83
Multivessel spasm 1.51 0.94–2.45 0.09
Calcium-channel blocker 0.73 0.35–1.51 0.39
Long-acting nitrate 1.35 0.89–2.07 0.17
Antiplatelet 1.43 0.94–2.20 0.10
Beta-blocker 2.34 1.08–5.06 0.032
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.(p ¼ 0.037), indicating the adequacy of the ﬁnal model
consisting of 7 variables (Table 3).
Derivation of the JCSA risk score. Five signiﬁcant
predictors selected from the multivariable Cox model were
assigned integer score proportional to their respective HR
for MACE (Table 3). The variables with a statistical trend,
such as ST-segment elevation during angina attack and the
use of beta-blockers were uniformity assigned 1 point.
Subsequently, these 7 predictors were integrated into the
JCSA risk scoring system. The risk score was then calculated
based on the sum of weighted predictors present in indi-
vidual patients. The distribution of the scoring points and
corresponding incidence of MACE is shown in Figure 1.
The score ranged from 0 to 9 points among the study
patients. The incidence of MACE was progressively
increased with an increase in the risk score.
For simplicity, 3 risk strata were deﬁned in accordance
with the scoring points; low (score 0 to 2, n ¼ 598),
intermediate (score 3 to 5, n ¼ 639) and high (score 6 or
more, n ¼ 192). The incidence of MACE in the low-,
intermediate-, and high-risk patients were 2.5%, 7.0%, and
13.0%, respectively (p < 0.001) (Fig. 2A). The Kaplan-
Meier curve for MACE between the 3 risk groups showed
clear prognostic utility of the scoring system throughout the
follow-up period (low vs. intermediate [p < 0.001]; low vs.
high [p < 0.001]; intermediate vs. high [p ¼ 0.007])
(Fig. 3). Even when the endpoint was limited to hard
MACE (cardiac death, nonfatal myocardial infarction, and
ICD shocks), the 3 risk strata showed their predictive
capacity (Fig. 2B). In contrast, as expected, the stratiﬁcationScore
Multivariable Analysis
HR 95% CI p Value Assigned Score
1.71 1.04–2.79 0.034 2
1.71 1.08–2.72 0.023 2
1.54 0.95–2.50 0.08 1
3.79 1.61–8.94 0.002 4
2.24 1.33–3.78 0.002 2
1.69 1.03–2.78 0.039 2
2.00 0.88–4.54 0.09 1
Figure 1 The JCSA Risk Scoring System and Corresponding Incidence of MACE
The scoring system consisted of 7 predictors of major adverse cardiac events (MACE). The total score was positively correlated with the incidence of MACE. JCSA ¼ Japanese
Coronary Spasm Association.
Figure 2
The 3 Risk Strata Classiﬁed Based on the JCSA Risk
Score and Corresponding Incidence of MACE
(A) The incidence of MACE. (B) The incidence of hard MACE, including cardiac
death, nonfatal myocardial infarction, and appropriate implantable cardioverter
deﬁbrillator shocks. Abbreviations as in Figure 1.
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(low-risk 1.2% vs. intermediate-risk 1.1% vs. high-risk
2.6%; p ¼ 0.25).
Application of the JCSA risk score to clinical subgroups. The
JCSA risk score was also applied to clinical subgroups
identiﬁed by patient characteristics and treatments.
Importantly, the Cox proportional hazard model forFigure 3
Kaplan-Meier Curve for MACE Between the
3 Risk Strata
Kaplan-Meier analysis demonstrated the prognostic difference between low-,
intermediate-, and high-risk patients throughout the follow-up period. Abbreviations
as in Figure 1.
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JCSA risk score is useful among various subgroups (Fig. 4).
Validation of the JCSA risk score. The JCSA risk score
was validated in the internal training and validation sets.
The random data partition was conducted 1,000 times,
and the rate for the prediction of risk strata was calculated
with each iteration. On average, the prediction rate was
86.6% (SD 10.0%) in the training set and 86.5% (SD
10.4%) in the validation set. The average incidence of
MACE was 3.0% for validation samples predicted to be
low-risk, 7.6% for intermediate-risk, and 13.0% for high-
risk (Fig. 5).
Discussion
The major ﬁndings of the present study were that: 1. the
JCSA risk score, in which 7 predictive factors derived from the
multivariable Cox model were integrated, showed a signiﬁcant
correlation with the prognosis of VSA patients; 2. the 3 risk
categories were classiﬁed based on the JCSA score and
provided clear risk stratiﬁcation of cardiac events, even
among various VSA subgroups; and 3. the JCSA risk score
showed an acceptable predictive capacity in the internal vali-
dation. To the best of our knowledge, this is the ﬁrst study that
has developed the useful clinical risk score for VSA patients.
Need for risk prediction tools for VSA. Since Prinzmetal
et al. (23) ﬁrst described VSA as a “variant angina” in 1959,
a number of studies have revealed the clinical characteristics and
outcomes of this disorder. The prognostic studies with
hundreds of VSA patients were performed in the 1980s
demonstrating that 5-year survival rate free from death
or myocardial infarction were 77% to 97% and 60% to 83%,
respectively (7–9), whereas the patient outcomes appear to have
improved in the 2000s (5,11,12,24). Several prognostic factors
for VSA, such as smoking, organic coronary stenosis, and
multivessel spasm, have been established (6–10,12). Recently,
we have also conﬁrmed the importance of these well-known
predictors, and newly identiﬁed the prognostic impact of
history of OHCA (13) and speciﬁc angiographic ﬁndings
during the diagnostic provocation tests (14) from the multi-
center registry study,which shares the samepopulationwith the
present study. These lines of evidence have contributed to
a better understanding of VSA. However, to apply such
prognostic ﬁndings to clinical practice, the accumulation of
various prognostic factors in individual patients should be taken
into consideration. In addition, it is conceivable that potential
interactions among those prognostic factors exist, making it
difﬁcult to assess individual prognosis. Thus, the comprehen-
sive assessment tool that provides the valid risk prediction in
individual patients needs to be developed. As a useful tool for
clinical risk prediction, simple scoring systems have been
devised for several disorders (15). The well-established scoring
systems include the TIMI (Thrombolysis In Myocardial
Infarction) risk score and the CADILLAC (Controlled
Abciximab andDevice Intervention toLowerLateAngioplasty
Complications) risk score (25,26), in which the weightedclinical variables selected from multivariable logistic regression
model provide an estimation of 30-day and 1-year mortality of
patients with myocardial infarction. The present study
demonstrates that the JCSA risk score provides the useful risk
assessment for VSA patients.
The JCSA risk score for VSA patients. Although VSA
patients are often thought to have relatively favorable
outcomes, their clinical risk varies considerably depending
on patient characteristics and treatments. The accurate risk
stratiﬁcation for future adverse events may contribute to an
appropriate patient management, which could be provided
by the JCSA risk scoring system. In the present study, the
risk score had a good correlation with patient outcome
(Fig. 1). The 3 risk strata deﬁned in accordance with the
scoring points found that there were 2- to 3-fold relative
increases in risk for MACE for each rise in the stratum. In
addition, the 3 risk strata provided the prognostic stratiﬁ-
cation, even for various clinical subgroups (Fig. 4), sug-
gesting the wide applicability of the scoring system.
The JCSA scoring system consisted of 7 predictive factors
for MACE identiﬁed by the multivariable Cox model
(Table 3). The clinical signiﬁcance of these predictors for
VSA patients has been consistently shown in the previous
studies (6–10,12,27), suggesting its adequacy. Interestingly,
rather than indicating the importance of common cardio-
vascular risks or structural abnormalities, the scoring system
emphasizes the signiﬁcance of characteristic clinical ﬁndings
reﬂecting or affecting disease activity of VSA. This is espe-
cially the case with angina at rest alone and ST-segment
elevation during an attack that may represent the occur-
rence of serious occlusive spasm, and thereby may be one of
the indicators that reﬂect the severity of this disorder.
Meanwhile, the use of beta-blockers could be an avoidable
risk (28–30). The beta-blockers are thought to have an
aggravating effect on VSA due to inhibition of beta-
adrenergic receptor-mediated coronary vasodilatation,
unmasking alpha-adrenoceptor-mediated coronary vaso-
constriction, and increasing vascular permeability to calcium
(31). Although beta-blockers could be considered when
combined with structural disorder or other conditions, its
tolerability may need to be measured by reference to the
present risk score.
When applying the JCSA risk score to clinical practice,
it may be a major concern whether the scoring system
sufﬁciently predicts the outcomes of VSA patients. Because
the comparable external dataset were not available in the
present study, we alternatively validated the scoring system
in the internal training and validation sets as the second best
policy. The average prediction rate of the scoring system in
the validation set was approximately 90%. Although the
rigorous validation should be performed in the independent
datasets, the present scoring system appears to have an
acceptable reliability for clinical use.
It should be noted that the JCSA risk score was derived
from the study population in whom adequate medical
treatments were provided. As ﬁrst-line therapy for VSA
Figure 4 Hazard Ratios for MACE Between the 3 Risk Strata According to Clinical Subgroups
Coronary risk factor includes hypertension, dyslipidemia, diabetes mellitus, and smoking. Organic coronary stenosis includes nonsigniﬁcant and signiﬁcant stenosis.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CI ¼ conﬁdence interval; pts ¼ patients; ref ¼ reference; other abbreviations as
in Figure 1. Continued on the next page.
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90% of the patients (Table 1). Also, about one-half of the
patients were additionally treated with long-acting nitrates
and antiplatelets For this reason, the present risk score
should be applied on the premise that the patients receive
standard treatment for this disorder.
Clinical implications. The JCSA risk scoring system
assembled multiple prognostic factors and estimates future
adverse cardiac events in individual VSA patients. The clinical
information required for the present scoring system may be
readily available from routine practice, which helps clinicians
predict patient outcomes easily. The information on prog-
nostic stratiﬁcation may lead to personalized management,including the judgment of necessity for intensive medical
treatment and close follow-up. In addition, because the
outcomes of VSA patients could be aggravated by a rebound
phenomenon after careless discontinuation of medications
(13,33,34), it is of clinical signiﬁcance that the adherence in
high-risk patients could be enhanced through the awareness
raised by the risk score.
Study limitations. First, the present study was conducted
as an observational study and consisted of retrospective and
prospective designs. Because the retrospective population
accounted for the majority of study patients, the cause-result
relationship was not established. Furthermore, the follow-up
periods varied in individual patients and management
Figure 4 Continued
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Figure 5
Average Incidence of MACE Between the
3 Risk Strata in the Validation Set
The incidence of MACE was calculated in each random partition of the validation
process, and the average incidence was derived through the 1,000 times iteration.
Avg ¼ average; other abbreviations as in Figure 1.
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physician. Second, the composite primary endpoint was
used. Third, the means for capturing ST-segment changes
or arrhythmias during angina attacks were not standardized.
Because coronary spasm develops transiently and the fre-
quency of attack markedly varies in individual patients, it is
conceivable that the prevalence of these ECG ﬁndings was
underestimated. Fourth, the prognostic impact of patient
adherence to medications during the follow-up period was
not evaluated. Fifth, the scoring system consisted of only
clinical variables that were available in the present registry
data. Thus, some important predictors may possibly be
missed. Sixth, the scoring system was not validated in the
independent external datasets; its usefulness should be
examined in future studies. Seventh, the prediction of
all-cause mortality is not sufﬁcient. The present scoring
system did not show the predictive capacity of this end-
point. However, despite these limitations, the present JCSA
risk score should merit emphasis for better understanding
and management of VSA patients.
Conclusions
The present multicenter study by the Japanese Coronary
Spasm Association developed the novel clinical risk predic-
tion score for VSA patients. The JCSA risk score, in which
established prognostic factors are integrated provides the
comprehensive risk assessment and prognostic stratiﬁcation
for VSA patients.
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